BioCryst Pharmaceuticals (NASDAQ:BCRX) Upgraded to Buy by StockNews.com

BioCryst Pharmaceuticals (NASDAQ:BCRX) was upgraded by StockNews.com from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Tuesday.

Several other research analysts also recently commented on the company. JMP Securities increased their price objective on BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the company a “market outperform” rating in a research note on Tuesday. Barclays increased their target price on shares of BioCryst Pharmaceuticals from $6.00 to $7.00 and gave the company an “equal weight” rating in a research report on Tuesday. Royal Bank of Canada reissued an “outperform” rating and issued a $10.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday. Finally, Needham & Company LLC reissued a “buy” rating and issued a $12.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, May 7th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $14.17.

BioCryst Pharmaceuticals Stock Performance

Shares of BCRX stock traded up $0.36 on Tuesday, reaching $7.87. 3,848,845 shares of the company were exchanged, compared to its average volume of 3,410,858. BioCryst Pharmaceuticals has a 1 year low of $4.03 and a 1 year high of $7.93. The business has a 50-day moving average price of $6.75 and a 200 day moving average price of $5.79. The company has a market cap of $1.62 billion, a price-to-earnings ratio of -7.36 and a beta of 1.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.11. The firm had revenue of $109.30 million during the quarter, compared to analyst estimates of $98.30 million. During the same quarter in the previous year, the firm posted ($0.24) earnings per share. The company’s quarterly revenue was up 34.9% on a year-over-year basis. As a group, equities analysts anticipate that BioCryst Pharmaceuticals will post -0.65 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Steven K. Galson purchased 21,940 shares of the company’s stock in a transaction dated Monday, May 13th. The stock was acquired at an average price of $5.49 per share, with a total value of $120,450.60. Following the purchase, the director now directly owns 51,551 shares in the company, valued at approximately $283,014.99. The acquisition was disclosed in a document filed with the SEC, which is available at this link. In other BioCryst Pharmaceuticals news, Director Nancy J. Hutson acquired 5,000 shares of the business’s stock in a transaction that occurred on Monday, May 20th. The stock was purchased at an average cost of $6.38 per share, with a total value of $31,900.00. Following the transaction, the director now owns 86,818 shares of the company’s stock, valued at $553,898.84. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Steven K. Galson acquired 21,940 shares of BioCryst Pharmaceuticals stock in a transaction that occurred on Monday, May 13th. The stock was bought at an average price of $5.49 per share, for a total transaction of $120,450.60. Following the completion of the acquisition, the director now owns 51,551 shares in the company, valued at approximately $283,014.99. The disclosure for this purchase can be found here. Insiders have bought 103,601 shares of company stock valued at $596,338 over the last ninety days. Company insiders own 4.80% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of BCRX. Los Angeles Capital Management LLC boosted its position in shares of BioCryst Pharmaceuticals by 8.9% during the second quarter. Los Angeles Capital Management LLC now owns 97,577 shares of the biotechnology company’s stock worth $603,000 after buying an additional 7,963 shares during the period. TD Asset Management Inc acquired a new position in BioCryst Pharmaceuticals during the 2nd quarter worth about $1,487,000. Rhumbline Advisers boosted its holdings in BioCryst Pharmaceuticals by 6.3% during the 2nd quarter. Rhumbline Advisers now owns 318,665 shares of the biotechnology company’s stock valued at $1,969,000 after acquiring an additional 18,916 shares during the period. nVerses Capital LLC acquired a new position in BioCryst Pharmaceuticals in the 2nd quarter valued at about $63,000. Finally, Signaturefd LLC increased its stake in BioCryst Pharmaceuticals by 560.5% during the second quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 5,599 shares during the period. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.